Literature DB >> 7427657

Systemic lupus erythematosus induced by aminoglutethimide.

M McCraken, E A Benson, P Hickling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7427657      PMCID： PMC1714627          DOI： 10.1136/bmj.281.6250.1254

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  4 in total

1.  Autoantibodies in patients with carcinoma of the breast. Correlation with prognosis.

Authors:  J Wasserman; U Glas; H Blomgren
Journal:  Clin Exp Immunol       Date:  1975-03       Impact factor: 4.330

2.  Lupus-like syndrome associated with carcinoma of the breast.

Authors:  H W Wallach
Journal:  Arch Intern Med       Date:  1977-04

3.  Thyroid and other autoantibodies in British and Japanese women: an epidemiological study of breast cancer.

Authors:  I Mittra; J Perrin; S Kumaoka
Journal:  Br Med J       Date:  1976-01-31

4.  Autoantibodies in early breast cancer: a stage-related phenomenon?

Authors:  A R Turnbull; D T Turner; J D Fraser; R S Lloyd; C J Lang; R Wright
Journal:  Br J Cancer       Date:  1978-09       Impact factor: 7.640
  4 in total
  4 in total

Review 1.  Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.

Authors:  P E Lønning; S Kvinnsland
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 2.  First generation aromatase inhibitors--aminoglutethimide and testololactone.

Authors:  G Cocconi
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 3.  Aromatase inhibitors in malignant diseases of aging.

Authors:  D C Johannessen; P E Lønning
Journal:  Drugs Aging       Date:  1992 Nov-Dec       Impact factor: 3.923

Review 4.  Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: A review.

Authors:  George Zarkavelis; Aristomenes Kollas; Eleftherios Kampletsas; Vasilis Vasiliou; Evripides Kaltsonoudis; Alexandros Drosos; Hussein Khaled; Nicholas Pavlidis
Journal:  J Adv Res       Date:  2016-04-23       Impact factor: 10.479
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.